The investment from the Coalition for Epidemic Preparedness Innovations (CEPI) will support the development of an mRNA vaccine. DIOSynVax, led by Professor Jonathan Heeney, Head of the Laboratory of Viral Zoonotics, University of Cambridge, will design and select the lead antigen through proof-of-concept preclinical studies, and undertake initial clinical development through Phase I/II studies.

DIOSynVax uses the combination of protein structure, computational biology and immune-optimisation to maximise the protection that vaccines can provide against global threats including existing and future virus outbreaks. Its vaccine candidates can be deployed in a variety of vaccine delivery and manufacturing platforms.

Reference Link:https://www.cam.ac.uk/research/news/cambridge-vaccine-expert-in-42million-partnership-to-develop-future-proofed-coronavirus-vaccines